Testing Experimental Medication in Healthy Subjects
common.study.values.description
“A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis”
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - RPT193
Antagonist of the CCR4 chemokine receptor
Drug - Placebo
Matching placebo
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
common.study.values.clinical-trial-id
NCT04271514
participant.views.study.view.id
dBBx2d
